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ABSTRACT
Introduction There is evidence that BCG immunisation 
may protect against unrelated infectious illnesses. 
This has led to the postulation that administering BCG 
before unrelated vaccines may enhance responses to 
these vaccines. This might also model effects of BCG on 
unrelated infections.
Methods and analysis To test this hypothesis, we 
have designed a randomised controlled trial of BCG 
versus no BCG immunisation to determine the effect 
of BCG on subsequent unrelated vaccines, among 
300 adolescents (aged 13–17 years) from a Ugandan 
birth cohort. Our schedule will comprise three main 
immunisation days (week 0, week 4 and week 28): BCG 
(or no BCG) revaccination at week 0; yellow fever (YF- 
17D), oral typhoid (Ty21a) and human papillomavirus 
(HPV) prime at week 4; and HPV boost and tetanus/
diphtheria (Td) boost at week 28. Primary outcomes 
are anti- YF- 17D neutralising antibody titres, Salmonella 
typhi lipopolysaccharide- specific IgG concentration, IgG 
specific for L1- proteins of HPV-16/HPV-18 and tetanus and 
diphtheria toxoid- specific IgG concentration, all assessed 
at 4 weeks after immunisation with YF, Ty21a, HPV and Td, 
respectively. Secondary analyses will determine effects 
on correlates of protective immunity (where recognised 
correlates exist), on vaccine response waning and on 
whether there are differential effects on priming versus 
boosting immunisations. We will also conduct exploratory 
immunology assays among subsets of participants to 
further characterise effects of BCG revaccination on 
vaccine responses. Further analyses will assess which 
life course exposures influence vaccine responses in 
adolescence.
Ethics and dissemination Ethics approval has 
been obtained from relevant Ugandan and UK ethics 
committees. Results will be shared with Uganda Ministry 
of Health, relevant district councils, community leaders 
and study participants. Further dissemination will be done 
through conference proceedings and publications.
Trial registration number ISRCTN10482904.
INTRODUCTION
There is increasing evidence that BCG immu-
nisation has non- specific, protective effects 
relating to infections other than tubercu-
losis.1–4 Experimental studies using BCG 
suggest that effects on the innate immune 
Strengths and limitations of this study
 ► This will be the first well- powered trial to investigate 
effects of BCG revaccination on responses to unre-
lated vaccines in adolescents.
 ► Effects on both live- attenuated and inert vaccines 
will be studied.
 ► Our robust immunoepidemiological design and 
nested immunological studies will address specific 
hypotheses regarding pathways of effects of BCG 
immunisation on unrelated vaccine responses.
 ► One limitation is that interaction between the three 
vaccines administered together 1 month after BCG 
immunisation may mask the true effect of BCG re-
vaccination on individual vaccine responses.  on M
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response are an important component of this phenom-
enon: BCG immunisation induces lasting epigenetic 
modification of innate immune cells, including mono-
cytes, macrophages and natural killer cells.5–8 This 
process, by which the innate immune system develops a 
form of memory, has been called ‘trained innate immu-
nity’.9 Evidence that a range of stimuli, including bacterial 
products (particularly Salmonella typhi lipopolysaccharide 
(LPS)), and infections, including malaria and hepatitis 
B,10 may induce trained innate immunity; that the profile 
into which cells are trained varies with the dose and char-
acteristics of the stimulus; and that effects may be induced 
prenatally (on exposure to maternal infections) as well as 
later in life9 is accumulating .
It is plausible that variation in the intensity and spec-
trum of experience of previous infections, and hence 
the epigenetic programming and consequent functional 
profiles of innate immune cells, contributes to the many 
differences in immunological activity observed between 
geographically and environmentally distinct settings, and 
hence to differences in vaccine response. If this hypoth-
esis is correct, BCG immunisation can act as a model for 
the effects of prior infection and may also be a tool for 
inducing enhanced benefits for other vaccines. Vaccine- 
specific responses can also act as a model for responses 
to infection. This is especially relevant given the current 
interest in the potential benefit of BCG immunisation 
against COVID-19 disease.11 12
In Europe, BCG vaccination 2 weeks before influenza 
vaccination has been shown to result in enhanced anti-
body responses to influenza proteins.13 BCG immunisa-
tion 4 weeks before yellow fever (YF 17D) vaccination has 
also been found to result in reduced replication of the 
YF vaccine virus; this was not associated with a significant 
reduction in the desired neutralising antibody response 
to YF or in the interferon-γ response, but the study size 
was small and may not have had sufficient power to 
demonstrate important effects.14
In Uganda, BCG immunisation at birth is recom-
mended.15 The benefits of BCG immunisation in adoles-
cence for protection against tuberculosis are not known 
and may differ between settings.16 Whether BCG immu-
nisation in adolescents in Uganda will have non- specific 
effects on the innate immune response, on subsequent 
immunisations and (indeed) on general health (given 
the prior exposure at birth and the ongoing exposure 
to non- tuberculous mycobacteria and other infections) 
is not known. In protocol C of the ‘POPulation differ-
ences in VACcine responses’ programme (POPVAC C), 
we plan to address this knowledge gap by randomising 
adolescent members of the Entebbe Mother and Baby 
Study (EMaBS) birth cohort15 in a nested trial of BCG 
revaccination versus no BCG revaccination before immu-
nisation with other vaccines. We summarise the protocol 
here.
HYPOTHESIS
The overarching goal of the POPVAC programme is to 
understand population differences in vaccine responses 
in Uganda, in order to identify strategies through which 
vaccine effectiveness can be optimised for the low- income, 
tropical settings where they are especially needed. This 
trial C is one of three parallel trials whose designs and 
cross- cutting analyses are described separately in this 
journal (bmjopen-2020-040425, bmjopen-2020-040426 
and bmjopen-2020-040427). For this trial C, we address 
the concept of trained innate immunity through the 
hypothesis that BCG immunisation modifies the response 
to subsequent unrelated vaccines.
OBJECTIVE
To determine whether BCG revaccination modulates 





Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) reporting guidelines17 are used. 
This trial will be a randomised, controlled, open, parallel 
group trial investigating the effect of BCG revaccination 
on unrelated vaccine response outcomes. The study 
will take place in Entebbe municipality, Wakiso district, 
Uganda, and will involve participants in the EMaBS birth 
cohort.15 In EMaBS, a cohort of 2500 pregnant women 
were recruited between 2003 and 2005 for a trial of anthel-
mintic treatment during pregnancy and early childhood, 
investigating effects on childhood vaccine responses 
and infectious disease incidence.15 We aim to enrol 300 
EMaBS birth cohort participants, randomising 150 to 
each intervention arm. All EMaBS participants received 
BCG at birth; hence, the current trial participants (in 
the BCG intervention arm) will undergo revaccination. 
EMaBS participants are expected to be aged 13–17 during 
recruitment to this study. As part of the ongoing cohort 
follow- up, participants will be encouraged to attend the 
clinic for interim illness events, and all serious adverse 
events, including hospitalisations, will be documented.
Recruitment criteria
Inclusion criteria
1. A participant of the EMaBS.15
2. Written informed consent by parent or guardian.
3. Written informed assent by participant.
4. Willing to remain in the study area for the duration of 
the study.
5. Willing to provide locator information and to be con-
tacted during the course of the trial.
6. Women agree to avoid pregnancy for the duration of 
the trial.
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7. Able and willing (in the investigator’s opinion) to com-
ply with all the study requirements.
Exclusion criteria
1. Concurrent enrolment into another clinical trial.
2. Clinically significant history of immunodeficiency 
(including HIV), cancer, cardiovascular disease, gas-
trointestinal disease, liver disease, renal disease, en-
docrine disorder and neurological illness.
3. A history of serious psychiatric condition or disorder.
4. Moderate or severe acute illness characterised by 
any of the following symptoms: fever, impaired con-
sciousness, convulsions, difficulty in breathing and 
vomiting, or as determined by the attending project 
clinician.
5. A history of previous immunisation with YF, oral ty-
phoid (Ty21a) or human papillomavirus (HPV) vac-
cine; previous immunisation with BCG or tetanus/
diphtheria (Td) vaccine at age ≥5 years.
6. Concurrent oral or systemic steroid medication or 
the concurrent use of other immunosuppressive 
agents within 2 months prior to enrolment.
7. A history of allergic reaction to immunisation or any 
allergy likely to be exacerbated by any component of 
the study vaccines, including egg or chicken proteins.
8. Tendency to develop keloid scars.
9. Positive HIV serology.
10. Positive pregnancy test.
11. Women currently lactating, with confirmed pregnan-
cy or with intention to become pregnant during the 
trial period.
12. Use of an investigational medicinal product or non- 
registered drug, live vaccine or medical device other 
than the study vaccines for 30 days prior to dosing 
with the study vaccine, or planned use during the 
study period.
13. Administration of immunoglobulins and/or any 
blood products within the 3 months preceding the 
planned trial immunisation date.
Interventions
We will randomise participants to receive BCG or not to 
receive BCG 4 weeks before immunisation with a panel 
of licensed unrelated vaccines (discussed below). The 
adolescents in the intervention arm will receive a dose of 
0.1 mL of BCG- Russia (Serum Institute of India) in the 
deltoid region of the right upper arm.
Randomisation and allocation to treatment arm
An independent statistician will generate the randomis-
ation code using a randomly permuted block size. This 
code will be embedded as a web- based randomisation 
system in REDCap (Research Electronic Data Capture) 
software.18 19 Randomisation to the two trial arms will be 
done in a 1:1 ratio. At enrolment, eligibility criteria will 
be checked and eligible participants will be allocated 
sequentially to the next randomisation number, with 
the corresponding trial arm designated in REDCap. The 
randomisation code will be kept securely by the trial stat-
istician with a second copy held by a data manager or stat-
istician not otherwise involved in the trial at the MRC/
UVRI and LSHTM Uganda Research Unit.
Blinding
This trial will not be blinded to clinicians or participants 
because they will not participate in outcome ascertain-
ment, and the expected development of a BCG skin 
reaction makes blinding difficult. It is unlikely that 
participants allocated to ‘no BCG’ will seek this privately. 
Only laboratory personnel evaluating vaccine response 
outcomes will be unaware of BCG allocation, so outcome 
ascertainment will not be biased through lack of blinding.
Immunisations
We anticipate that BCG revaccination may have different 
effects on live and non- live, oral and parenteral, and 
priming and boosting vaccines. Activated innate responses 
may kill live vaccines and suppress subsequent adaptive 
responses by this or other mechanisms,20 21 but bias, or 
even enhance, responses to toxoids or proteins22–24; 
thus, results from a single- vaccine study would not be 
generalisable.
We therefore propose to study a portfolio of licensed 
vaccines (live and inert, oral and parental, priming and 
boosting) expected to be beneficial (in some cases, 
already given) to adolescents in Uganda. Our schedule 
table 1 and online supplemental table S1 will comprise 
three main immunisation days (week 0, week 4 and week 
28). Additional HPV immunisation will be provided 
for girls aged ≥14 years, and a second Td boost will be 
given after completion of the study to accord with the 
national Expanded Programme on Immunisation (EPI) 
routines, but the response to these will not specifically be 
addressed. Further rationale for the selection of vaccines 
is detailed in online supplemental information. Our 
schedule has been developed in consultation with the EPI 
programme and is cognisant of potential interference 
between vaccines.
Schedule of immunisation and sampling
The schedule of immunisation and sampling is outlined 
in online supplemental table S1. While optimal timings 
for outcome measures vary between vaccines, sampling 
at 8 weeks after BCG and at 4 weeks after YF- 17D, Ty21a, 
HPV and Td is proposed for the primary end points, 
targeting the establishment of memory responses and 
approximate peak of antibody responses. A secondary 
end point at 1 year will assess waning. All analyses will take 
baseline measurements into account. Immunisation post-




These will be assessed in all participants.
1. YF- 17D: Neutralising antibody titres (plaque- reduction 
neutralisation test) at 4 weeks after YF immunisation.
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2. Ty21a: Salmonella typhi LPS- specific IgG concentration 
at 4 weeks after Ty21a immunisation.
3. HPV: IgG specific for L1- proteins of HPV-16/HPV-18 
at 4 weeks after HPV priming immunisation.
4. Td: Tetanus and diphtheria toxoid- specific IgG con-
centration at 4 weeks after Td immunisation.
Secondary outcomes
These will be assessed in all participants and will further 
investigate estimates of protective immunity (for vaccines 
where these are available) and dynamics of the vaccine 
responses, as well as the impact of the interventions on 
parasite clearance.
1. Protective immunity: Proportions with protective neu-
tralising antibody (YF), protective IgG levels (TT)25 
and seroconversion rates (Ty21a) at 4 weeks after the 
corresponding immunisation.
2. Response waning: Primary outcome measures (all vac-
cines) repeated at week 52 and area- under- the curve 
analyses. Parasitic infection may accelerate,26 and anti-
parasitic interventions may delay, waning.
3. Priming versus boosting: Effects on priming versus 
boosting will be examined for HPV only, comparing 
outcomes 4 weeks after the first and 4 weeks after the 
second vaccine dose.
Furthermore, our sample collection will offer oppor-
tunities for an array of exploratory immunological eval-
uations on stored samples, focusing mainly on vaccine 
antigen- specific outcomes. Exploratory assays will provide 
further detail on the mechanisms underlying effects of 
BCG on responses to unrelated vaccines. Such assays will 
assess the effects of revaccination with BCG on the profile 
of cellular phenotypes established before immunisation 
with the later- scheduled vaccines. For example, samples 
collected will provide opportunities for profiling using 
mass and flow cytometry, markers of immune activation 
and regulation, and gene expression studies.
Additional measurements
Other additional assays are discussed in online supple-
mental information and will comprise evaluation of 
helminth and malaria infection exposure, HIV serology 
(at baseline), pregnancy and full blood count testing (at 
baseline and before immunisation on each immunisation 
day).
Sample size considerations
Based on the literature20 27 28 and preliminary data, we 
anticipate that SDs of primary outcome measures will lie 
between 0.3 and 0.6 log10, and that revaccination with 
BCG may increase responses by approximately 0.12–0.14 
log10. Based on these assumptions, we aim to enrol 300 
EMaBS participants (150 BCG revaccination, 150 no BCG 
revaccination). Allowing for 10% loss to follow- up, this will 
give over 90% power to detect a difference of 0.12 log10 in 
vaccine response between the pre- BCG immunised and 
non- pre- BCG immunised groups at 5% significance level 
and assuming vaccine response SD of 0.3 log10 (table 2).
Ethics and dissemination
Ethical approval has been granted from the Research 
Ethics Committees of the Uganda Virus Research Insti-
tute (reference: GC/127/19/05/682), the London 
School of Hygiene and Tropical Medicine (reference: 
16034), the Uganda National Council for Science and 
Technology (reference: HS 2491) and from the Uganda 
National Drug Authority (certificate number: CTA0094). 
Any protocol amendments will be submitted to ethics 
committees and regulatory bodies for approval before 
implementation.
Participants will be adolescents and therefore a 
vulnerable human population. Care will be taken to 
provide adequate age- appropriate and education- status- 
appropriate information, to ensure that it is understood 
and to emphasise that participation is voluntary. Partic-
ipants will be enrolled only when they have given their 
own assent and when consent has been given by the 
parent or guardian. No major risks to the participants are 
anticipated as all the vaccines to be given are licensed and 
known to be safe.
Regarding BCG immunisation or revaccination in 
adolescence, benefits with respect to protection against 




week 4 (Immunisation week 8)
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Non- live 
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*Prior BCG status may vary (data on history and documentation of prior BCG, and presence of a BCG scar, will be documented although 
these approaches have limitations for determining BCG status).
†The National Expanded Programme on Immunisation recommends three doses of HPV vaccine for older girls.
‡These doses will be given to comply with guidelines, but outcomes specifically relating to these doses will not be assessed.
§Priming by immunisation in infancy is assumed.
HPV, human papillomavirus; Td, tetanus/diphtheria.
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tuberculosis among Ugandan adolescents are unknown 
and may, at best, be modest. There may be non- specific 
benefits. WHO’s SAGE committee concluded, in their 
summary of October 2017,29 that
BCG revaccination is safe in Mycobacterium tuberculo-
sis infected and uninfected populations. There is a 
lack of evidence from randomised controlled trials 
and retrospective cohort and case- control studies 
demonstrating the efficacy and effectiveness of BCG 
revaccination in adolescents and adults after primary 
BCG vaccination in infancy for protection against TB 
disease. Due to absence of evidence, BCG revaccina-
tion is not considered cost- effective. Further research 
is warranted to explore whether certain sub- groups of 
age, geographic or M. tuberculosis exposure categories 
would benefit from BCG revaccination.
We hope, through this work, to contribute to this 
debate.
Study findings will be published through open access 
peer- reviewed journals and presentations at local, 
national and international conferences and to the local 
community through community meetings. Anonymised 
participant- level data sets generated will be available on 
request.
Patient and public involvement
The EMaBS research team has previously worked with 
volunteer local council field workers to ensure regular 
follow- up of participants, and these field workers 
continue to attend participants’ meetings and provide a 
mechanism by which the communities from which partic-
ipants are drawn can be informed about ongoing work. 
In addition, prior to the start of this study, we will share 
our plans with district health and education officers and 
with colleagues at Entebbe Hospital. We will establish an 
advisory committee of parents who will help us ensure 
that EMaBS cohort members can participate in the study 
without undue disruption to their school work. Study 
findings will be shared with these stakeholders and with 
participants.
Data management and analysis
Sociodemographic information and clinical and labora-
tory measurements will be recorded and managed using 
REDCap tools,18 19 with paper- based forms as backup. All 
data will be recorded under a unique study ID number. 
When paper forms must be used, data will be double- 
entered in a study- specific database, with standard checks 
for discrepancies. All data for analysis will be anonymised 
and stored on a secure and password- protected server, 
with access limited to essential research personnel.
The effect of BCG versus no BCG revaccination on the 
outcomes will be analysed, including subgroup analysis 
by sex. The analysis will test whether BCG preimmuni-
sation alters the response to live or inert vaccines given 
after 4 weeks, including effects on vaccine replication, 
immune response profile, priming, boosting and waning. 
It will indicate whether including BCG as a component 
of school- based immunisation schedules is likely to have 
non- specific benefits for Ugandan adolescents.
DISCUSSION
It is increasingly clear that several live vaccines, including 
BCG, measles vaccine and Vaccinia (smallpox) vaccine, 
have non- specific, beneficial, effects, including reduced 
mortality (not related to the infectious disease that they 
were designed to target).1 2 The potential effects of BCG 
on responses to unrelated vaccines, specifically on live- 
attenuated ones such as YF and Ty21a, might model its 
effects on responses to unrelated infectious agents.
In contrast, non- specific negative effects have been 
associated with inactivated vaccines such as diphtheria–
tetanus–pertussis (DTP). A high childhood mortality has 
been observed among girls vaccinated with DTP.30 31 It has 
been further suggested that reducing time of exposure to 
DTP as the most recent vaccination with BCG may reduce 
this childhood mortality.30
We hypothesise that BCG immunisation both achieves 
non- specific benefits and influences vaccine responses 
through mechanisms based on effects on the innate 
immune system and consequent immunological profile.
Of note, in this Ugandan birth cohort, all participants 
were documented to have received BCG at birth, with 
the strain of BCG used recorded.15 This will therefore 
be the first well- powered study to investigate effects of 
BCG revaccination on vaccine responses in adolescents. 
Table 2 Power estimates (5% significance level)
SD (log10)
Log10 difference
0.08 0.10 0.12 0.14 0.16 0.18 0.20
Trial C: 150 BCG immunisation vs 150 no BCG immunisation
0.3 59% 78% 91% 97% 99% >99% >99%
0.4 37% 53% 69% 82% 91% 96% 98%
0.5 26% 37% 50% 63% 75% 84% 91%
0.6 19% 28% 37% 48% 59% 69% 78%
Cells highlighted in grey correspond to >80% power.
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It will not investigate the effects of a first dose of BCG in 
adolescence.
For this work, all participants will receive BCG- Russia 
strain, provided by the Serum Institute of India. While 
responses to strains vary, this strain is widely available 
globally and in use in Uganda. For comparability, it will 
be used across the three trials, POPVAC A, POPVAC B 
and POPVAC C. In the context of these trials, it will not 
be possible to determine whether different strains of BCG 
would have different effects on other vaccines.
This study will determine whether BCG immunisation 
alters the response to live or inert vaccines given after 4 
weeks, including effects on vaccine replication, immune 
response profile, priming, boosting and waning among 
adolescents who received BCG as infants. It will indicate 
whether including BCG as a component of school- based 
immunisation schedules is likely to have non- specific 
benefits for Ugandan adolescents and other settings 
where infant BCG immunisation is common. If this is 
correct, BCG immunisation may be used as a tool for 
inducing enhanced benefits for other vaccines in a wide 
range of settings.
Study timeline
Applications for ethical approval were submitted in May 
2018, with approval received in September 2018 (Uganda 
Virus Research Institute Research Ethics Committee), 
May 2019 (National Drug Authority and Uganda National 
Council for Science and Technology) and June 2019 
(London School of Hygiene and Tropical Medicine). 
Collaborator/investigator/trial steering committee meet-
ings were also held during the initial 12- month planning 
period. Recruitment is scheduled to commence in May 
2020. Intervention will be up to 12 months, with comple-
tion of the project scheduled for April 2022.
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